



# «Adenomi cancerizzati» l'approccio diagnostico


**Romano Sassatelli**


**Gastroenterologia Endoscopia Digestiva**

**AUSL IRCCS di Reggio Emilia**



# T1 : di cosa parliamo

di un cancro con caratteristiche  
morfologiche per cui  
si è ritenuta possibile  
l'asportazione endoscopica  
con intento radicale







## Gastrointestinal: Sessile serrated adenoma/polyps with a minute T1 colorectal carcinoma



# Cosa succede, di solito

	$\leq T1$	$> T1$ o $T1$ AR
Biopsie e chirurgia	Overtreatment	
Asportazione endoscopica		Biologia / Inadeguato trattamento

Pazienti con diagnosi istologica di polipo cancerizzato del colon retto,  
dopo **asportazione** giudicata **completa** dall'endoscopista.

*Studio Sec-Giscor (criteri di inclusione)*





Table 7.1: Adaptation of the revised Vienna classification<sup>1</sup> for colorectal cancer screening



European guidelines for quality assurance in colorectal cancer screening and diagnosis *First Edition*

**1. NO NEOPLASIA:<sup>2</sup>**

Vienna Category 1 (Negative for neoplasia)

**2. MUCOSAL LOW GRADE NEOPLASIA:**

Vienna Category 3 (Mucosal low-grade neoplasia

Low-grade adenoma

Low-grade dysplasia);

Other common terminology

mild and moderate dysplasia;

WHO: low-grade intra-epithelial neoplasia

**3. MUCOSAL HIGH GRADE NEOPLASIA:**

Vienna: Category 4.1–4.4 (Mucosal high grade neoplasia

High-grade adenoma/dysplasia

Non-invasive carcinoma (carcinoma *in situ*)

Suspicious for invasive carcinoma

Intramucosal carcinoma);

Other common terminology

severe dysplasia;

high-grade intraepithelial neoplasia;

WHO: high-grade intraepithelial neoplasia

TNM: pTis

**4. CARCINOMA** invading the submucosa or beyond:

4a. Carcinoma confined to submucosa

Vienna: Category 5 (Submucosal invasion by carcinoma);

TNM: pT1

4b. Carcinoma beyond submucosa

TNM: pT2–T4




## Management of pT1 colorectal cancer

- 8.16 If there is clinical suspicion of a pT1 cancer, a site of excision should be marked with sub-mucosal India ink **(VI - C)**.<sup>Sect 8.4.1</sup>
- 8.17 Where a pT1 cancer is considered high-risk for residual disease consideration should be given to completion colectomy along with radical lymphadenectomy, both for rectal cancer **(II - A)** and colon cancer **(VI - A)**. If surgical resection is recommended, consideration should be given to obtaining an opinion from a second histopathologist as variation exists in evaluating high risk features (see also Ch. 7, Rec. 7.7) **(VI - B)**.<sup>Sect 8.4.2; 7.5.3</sup>
- 8.18 After excision of a pT1 cancer, a standardised follow-up regime should be instituted **(VI - A)**. The surveillance policy employed for high-risk adenomas is appropriate for follow-up after removal of a low-risk pT1 cancer (see Ch. 9, Rec. 9.16) **(III - B)**.<sup>Sect 8.4.3; 9.5.1</sup>

pT1 cancers can be categorised into low-risk and high-risk lesions according to their likelihood of being associated with lymph node metastases:

- Low risk: Well or moderately differentiated and no lymphovascular invasion; rate of lymph node metastases <5%
- High risk: Poorly differentiated and/or lymphovascular invasion; rate of lymph node metastases ~35%

The significance of venous invasion is currently unknown.




# Polipi pedunculati

Figure 7.2: Haggitt levels of invasion in polypoid carcinomas

---



Level 1:  
invasion of the  
submucosa but  
limited to the head  
of the polyp



Level 2:  
invasion extending  
into the neck of  
polyp



Level 3:  
invasion into any  
part of the stalk




Level 4:  
invasion beyond the  
stalk but above the  
muscularis propria

---


# Polipi sessili


Figure 7.1: Kikuchi levels of submucosal infiltration modified from Nascimbeni et al. (2002)



Kikuchi cannot be used in the absence of muscularis propria  
Haggitt is not applicable in non-polypoid lesions, and measurement depends on a  
recognisable submucosa from which to measure

**Figure 2** Measurement of the depth of sub-mucosal invasion of colorectal carcinoma. (a) When the level of the muscularis mucosae can be detected or presumed, the distance from the muscularis mucosae to the tumor apex is measured. (b,c) When the level of the muscularis mucosae cannot be detected or presumed, the distance from the tumor surface to the tumor apex is measured. (b, sessile polyp; c, pedunculated polyp). (d) If a pedunculated polyp involves the muscularis mucosae (such as a Peutz-Jeghers polyp), the distance from the neck to the tumor apex is measured (deeper than Haggitt level 2).





# Caveat

- **Are we accurately measuring depth of SM invasion mm vs Kikuchi?**

(Haboubi, Colorect Dis 2013)

- **Condition of muscularis mucosae (< for clearly identified) as a risk factor for LNM**

(Nakadoi, Surg Endosc 2014)

# Integrating European GL

Invasione linfatici (vascolare), margini, profondità di invasione,  
Grading, Budding in funzione di LNM (SYST REV)

Evidenze di efficacia ET/surgery in popolazione,  
variabilità di trattamento



# Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer

C. Beaton\*, C. P. Twine\*, G. L. Williams\* and A. G. Radcliffe†

\*Department of Colorectal Surgery, Royal Gwent Hospital, Newport, UK and †Screening Division, Public Health Wales, Cardiff, UK

Received 18 June 2012; accepted 4 September 2012; Accepted Article online 20 January 2013

Colorectal Disease © 2013 The Association of Coloproctology of Great Britain and Ireland. 15, 788–797

## Abstract

**Aim** Lymph node (LN) metastases are present in up to 17% of early colorectal cancers (pT1). Identification of associated histopathological factors would enable counselling of patients regarding this risk.

**Method** Pubmed and Embase were employed utilizing the terms ‘early colorectal cancer’, ‘lymph node metastasis’, ‘submucosal invasion’, ‘lymphovascular invasion’, ‘tumour budding’ and ‘histological differentiation’. Analysis was performed using REVIEW MANAGER 5.1.

**Results** Twenty-three cohort studies including 4510 patients were analysed. There was a significantly higher risk of LN metastasis with a depth of submucosal invasion > 1 mm than with lesser degrees of penetration (OR 3.87, 95% CI 1.50–10.00,  $P = 0.005$ ). Lymphovascular invasion was significantly associated with LN

metastasis (OR 4.81, 95% CI 3.14–7.37,  $P < 0.00001$ ). Poorly differentiated tumours had a higher risk of LN metastasis compared with well or moderately differentiated tumours (OR 5.60, 95% CI 2.90–10.82,  $P < 0.00001$ ). Tumour budding was found to be significantly associated with LN metastasis (OR 7.74, 95% CI 4.47–13.39,  $P < 0.001$ ).

**Conclusion** Meta-analysis of the current literature demonstrates that in early colorectal cancer a depth of submucosal invasion by the primary tumour of > 1 mm, lymphovascular invasion, poor differentiation and tumour budding are significantly associated with LN metastasis.

**Keywords** Early colorectal cancer, lymph node metastasis, submucosal invasion, lymphovascular invasion, tumour budding, histological differentiation



# Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis

Shanshan Mou · Roy Soetikno · Tadakasu Shimoda · Robert Rouse · Tonya Kaltenbach

Surg Endosc (2013) 27:2692–2703

Received: 21 July 2012 / Accepted: 21 December 2012 / Published online: 8 February 2013  
© Springer Science+Business Media New York 2013

## Abstract

**Background** Colorectal adenocarcinoma with depth of invasion  $\leq 1,000 \mu\text{m}$  from the muscularis mucosa and favorable histology is now considered for local resection. We aimed to examine the strength of evidence for this emerging practice.

**Methods** We searched Medline, Scopus, and Cochrane (1950–2011), then performed a meta-analysis on the risk of lymph node metastasis in nonpedunculated (sessile and nonpolypoid) T1 colorectal cancers. We included studies with nonpedunculated lesions, actual invasion depth, and pathologic factors of interest. Synchronous, polyposis or secondary cancers, and chemoradiation studies were excluded. Our primary outcome was the risk of LNM. We analyzed using Review Manager; we estimated heterogeneity using Cochran Q  $\chi^2$  test and  $I^2$ . We generated summary risk ratios using a random effects model, performed sensitivity analyses, and evaluated the quality of evidence using GRADEPro.

**Results** We identified 209 articles; 5 studies ( $n = 1213$  patients) met the inclusion criteria. The risk of LNM in nonpedunculated  $\leq 1,000 \mu\text{m}$  is 1.9 % (95 % confidence interval 0.5–4.8 %). The risk for all T1 is 13 % (95 % confidence interval 11.5–15.4 %). Characteristics protective against LNM were  $\leq 1,000 \mu\text{m}$  invasion, well differentiation, absence of lymphatic and vascular invasion, and absence of tumor budding. We did not detect significant study heterogeneity. The quality of evidence was poor.

**Conclusions** Well-differentiated nonpedunculated T1 colorectal cancer invasive into the submucosa  $\leq 1,000 \mu\text{m}$ , without lymphovascular involvement or tumor budding, has the lowest risk of nodal metastasis. Importantly, the risk was not zero (1.9 %), and the qualitative formal analysis of data was not strong. As such, endoscopic resection alone may be adequate in select patients with submucosal invasive colorectal cancers, but more studies are needed. Overall, the quality of evidence was poor; data were from small retrospective studies from limited geographic regions.

# Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions

Endoscopy 2013; 45: 827–834

Authors

Steven L. Bosch<sup>1</sup>, Steven Teerenstra<sup>2</sup>, Johannes H. W. de Wilt<sup>3</sup>, Chris Cunningham<sup>4</sup>, Iris D. Nagtegaal<sup>1</sup>

**Background and study aim:** Population screening for colorectal cancer (CRC) is expected to increase the number of pT1 CRCs. Local excision is an attractive treatment option, but is only oncologically safe in the absence of lymph node metastasis (LNM). A systematic review of the predictive value of pathological risk factors for LNM in pT1 CRC was conducted to provide data for an evidence-based decision regarding follow-up or radical surgery after local excision.

**Methods:** PubMed was searched for reports on predictors of LNM in pT1 CRC. Published papers written in English and containing at least 50 patients were included. Meta-analyses were performed using Review Manager 5.1.

**Results:** A total of 17 studies were included involving a total of 3621 patients with available nodal status. The strongest independent predictors of LNM were lymphatic invasion (relative risk [RR]

5.2, 95% confidence interval [CI] 4.0–6.8), submucosal invasion  $\geq 1$  mm (RR 5.2, 95%CI 1.8–15.4), budding (RR 5.1, 95%CI 3.6–7.3), and poor histological differentiation (RR 4.8, 95%CI 3.3–6.9). Limitations of the study were: results could not be stratified according to location in the colon or rectum; very early tumors removed by polypectomy without surgical resection were not included in the meta-analysis; and included studies were primarily from Asian countries and results therefore need to be verified in Western populations.

**Conclusion:** The absence of lymphatic invasion, budding, submucosal invasion  $\geq 1$  mm, and poor histological differentiation were each associated with low risk of LNM. Risk stratification models integrating these factors need to be investigated further.

## Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer

Hiroo Wada · Manabu Shiozawa · Kayoko Katayama ·  
Naoyuki Okamoto · Yohei Miyagi · Yasushi Rino ·  
Munetaka Masuda · Makoto Akaike

### Abstract

**Background** In this study we examined whether histopathological findings, specifically lymphatic vessel invasion identified by an anti-human podoplanin antibody, and several other factors are associated with lymph node metastasis in T1 colorectal cancer.

**Methods** We searched PubMed and Cochrane Library, and also handsearched relevant journals, for reports written in English and published between 1998 and 2012, utilizing combination headings, such as ‘colorectal cancer,’ ‘lymph node metastasis,’ and ‘risk factors.’ For the report to be included in our study, the following criteria had to be met: (1) data on the frequency of lymph node metastasis in T1 colorectal cancer in relation to histopathological factors were reported; (2) patients had undergone bowel resection and had histologically diagnosed T1 colorectal cancer; (3) lymphatic vessel invasion was identified by immunohistochemistry with an anti-human podoplanin antibody rather

than by hematoxylin and eosin staining; (4) univariate and multivariate analyses were conducted. Studies investigating molecular markers were excluded. The independent predictive factors were confirmed in at least one study included in the meta-analysis in the present systematic review. Microsoft Excel 2013 for Windows was used for the statistical analysis.

**Results** Initially, 369 publications were identified in the database searches and handsearches, of which five ultimately met all of the inclusion criteria and selected for this systematic review. The meta-analysis revealed that only two factors were significantly associated with T1 colorectal cancer lymph node metastasis: (1) lymphatic vessel invasion identified by an anti-human podoplanin antibody [Mantel–Haenszel odds ratio (OR) 5.19; 95 % confidence interval (CI) 3.31–8.15;  $P = 0.01$ ]; (2) tumor budding (OR 7.45; 95 % CI 4.27–13.02;  $P = 0.0077$ ).

**Conclusion** Our meta-analysis revealed that lymphatic vessel invasion identified by an anti-human podoplanin antibody and tumor budding were significantly associated with T1 colorectal cancer lymph node metastasis.



# Endoscopic and surgical treatment of malignant colorectal polyps: a population-based comparative study

Rawad Mounzer, MD,<sup>1</sup> Ananya Das, MD,<sup>2</sup> Roy D. Yen, MD, MPH,<sup>1</sup> Amit Rastogi, MD,<sup>3</sup> Ajay Bansal, MD,<sup>3</sup> Lindsay Hosford, BA,<sup>1</sup> Sachin Wani, MD<sup>1,4</sup>

Denver, Colorado; Gilbert, Arizona; Kansas City, Missouri, USA

**Background:** Long-term population-based data comparing endoscopic therapy (ET) and surgery for management of malignant colorectal polyps (MCPs) are limited.

**Objective:** To compare colorectal cancer (CRC)-specific survival with ET and surgery.

**Design and Setting:** Population-based study.

**Patients:** Patients with stage 0 and stage 1 MCPs were identified from the Surveillance Epidemiology and End Results (SEER) database (1998-2009). Demographic characteristics, tumor size, location, treatment modality, and survival were compared. Propensity-score matching and Cox proportional hazards regression models were used to evaluate the association between treatment and CRC-specific survival.

**Interventions:** ET and surgery. No LNM

**Main Outcome Measurements:** Mid-term (2.5 years) and long-term (5 years) CRC-free survival rates and independent predictors of CRC-specific mortality.

**Results:** Of 10,403 patients with MCPs, 2688 (26%) underwent ET and 7715 (74%) underwent surgery. Patients undergoing ET were more likely to be older white men with stage 0 disease. Surgical patients had more right-sided lesions, larger MCPs, and stage 1 disease. There was no difference in the 2.5-year and 5-year CRC-free survival rates between the 2 groups in stage 0 disease. Surgical resection led to higher 2.5-year (97.8% vs 93.2%;  $P < .001$ ) and 5-year (96.6% vs 89.8%;  $P < .001$ ) CRC-free survival in stage 1 disease. These results were confirmed by propensity-score matching. ET was a significant predictor for CRC-specific mortality in stage 1 disease (hazard ratio 2.40; 95% confidence interval, 1.75-3.29;  $P < .001$ ).


**Limitations:** Comorbidity index not available, selection bias.

**Conclusions:** ET and surgery had comparable mid- and long-term CRC-free survival rates in stage 0 disease. Surgical resection is the recommended treatment modality for MCPs with submucosal invasion. (Gastrointest Endosc 2015;81:733-40.)


**TABLE 2. Comparison of CRC-free survival at 2.5 and 5 years after endoscopic therapy and surgery in patients with stage 0 (Tis) and stage 1 (T1N0) malignant colorectal polyps**

Variable	Endoscopic treatment (n = 2688)	Surgery (n = 7715)	P value
Overall 2.5-y CRC-free survival rate, %	95.9	97.7	<.001
Stage 0, %	97.6	97.5	.75
Stage 1, %	93.2	97.8	<.001
Overall 5-y CRC-free survival rate, %	94	96.5	<.001
Stage 0, %	96.3	95.9	.75
Stage 1, %	89.8	96.6	<.001

CRC, Colorectal cancer.



**Figure 2.** Kaplan-Meier colorectal cancer-specific survival curves comparing endoscopic therapy and surgical resection for patients with stage 0 colorectal cancer.



**Figure 3.** Kaplan-Meier colorectal cancer-specific survival curves comparing endoscopic therapy and surgical resection for patients with stage 1 colorectal cancer.

## Variability in management of T1 colorectal cancer in Wales

U Khalid, MD Evans, GL Williams, J Hanson, M Davies

on behalf of the Colorectal Cancer Subgroup of the National Specialist Advisory Group for Cancer, Wales, UK


### ABSTRACT

**INTRODUCTION** The management of T1 colorectal cancer is controversial. Surgical resection should offer cure in the majority of patients and can stage lymph nodes accurately. Nevertheless, there can be significant associated morbidity and it potentially risks overtreating the patient. Endoscopic/local excision has significantly reduced morbidity but risks undertreating undetected metastatic lymph nodes, thereby compromising oncological outcomes. The aim of this study was to review the practice across Wales over a two-year period.


**METHODS** Data on T1 tumours for the period of 2009–2011 were collected from the Cancer Network Information System Cymru.

**RESULTS** A total of 161 patients were diagnosed as having T1 colorectal cancer (without prior neoadjuvant treatment). The median age was 68 years (range: 14–91 years) and 66% of the patients were male. Forty-eight (30%) of these tumours were screen detected. There were 112 colonic and 49 rectal tumours. Ninety-five patients with colonic tumours (85%) underwent major surgical resections, 51% of which were laparoscopic. Forty patients with rectal cancers (82%) underwent major surgical resection and 45% of these procedures were laparoscopic. The rest of the patients underwent local excision in the form of endoscopic polypectomy or transanal resection.


**CONCLUSIONS** This study demonstrates that there is no consensus in the management of T1 disease across Wales. With the advent of screening and the development of more sophisticated endoscopic techniques, the decision of how to treat T1 colorectal cancer will become a more regular challenge for the colorectal multidisciplinary team. The treatment needs standardisation. For now, however, this balance of risk will need to be made on an individual patient basis.




**Figure 1** Distribution of T1 tumours according to tumour site



**Figure 3** Treatment for T1 cancers originating in the rectum



**Figure 2** Treatment for T1 cancers originating in the colon



**Figure 4** Treatment type by the different multidisciplinary teams in Wales




# The potential impact of local excision for T1 colonic cancer in elderly and comorbid populations: a decision analysis


Andrew C. Currie, MRCS,<sup>1</sup> Alan Askari, MRCS,<sup>1</sup> Christopher Rao, PhD, MRCS,<sup>2</sup>  
Brian P. Saunders, MD, FRCP,<sup>3,4</sup> Thanos Athanasiou, MD, PhD,<sup>4</sup> Omar D. Faiz, MS, FRCS,<sup>1,4</sup>  
Robin H. Kennedy, MS, FRCS<sup>1,4</sup>

Harrow, London, United Kingdom

Decision tree



Markov model



**Conclusions:** Under broad assumptions, endoscopic resection is a reasonable treatment option for both low-risk and high-risk T1 colonic cancer, particularly in elderly, comorbid patients. Exploration of methods to facilitate endoscopic resection of T1 colonic neoplasia appears warranted. (Gastrointest Endosc 2016;84:986-94.)



“Aiuto Molecolare”

**Table 2.** Molecular markers associated with the risk of lymph node metastasis in early colorectal cancer

---

Tumor suppressor genes and their products

p53 overexpression

Loss of p27 expression

Markers involved in tumor vascularization

Microvessel density

VEGF/VEGF-C

COX-2

Markers related to cell adhesion and invasion

E-cadherin

$\alpha$ -Catenin/ $\beta$ -catenin

CD44 variant 6

Additional markers identified by gene expression analysis

CITED1

---

- **MMR, p53, MSI not predictive**

(Wook Huh, J Surg Oncol 2014)

- **CD10 expression associated with LNM**

(Nishida Dis Col Rectum 2014)

- **Lymphatic invasion better identified with D2-40 immunostaining**

(Wada Int J Clin Oncol 2013)

- **No LNM in MSI-H**


(Kang Yonsei Med J 2015)

Il problema principale:  
come diagnosticare un  
T1  
(e come trattarlo)



# Obiettivi

---

- Identificare lesioni (pre)cancerose
- Effettuare una resezione endoscopica



*endoscope semi-flexible de Schindler*




# Endoscopia potenziata

---


- Immagine HD e zoom (o magnificazione)
  - Cromoendoscopia virtuale

# Alta definizione

---




...fino a 800k pixel







# Zoom o Magnificazione



# Zoom o Magnificazione




# NBI (narrow band imaging)



**OLYMPUS**


Your Vision, Our Future






# NBI (narrow band imaging)

---




# NBI (narrow band imaging)

---



# NBI (narrow band imaging)





# I-Scan


**PENTAX**



# BLI (Blue light imaging)

---

**FUJIFILM**  
Value from Innovation



ELUXEO™

**EXPERIENCE THE  
POWER OF LIGHT.**


It is time for the next generation of endoscopy systems:  
Fujifilm's innovative 4-LED Multi Light™ technology

BLI-EQUIPPED

The advertisement features a central circular inset showing a close-up of a brain's surface, illuminated with a blue light. To the left, a black endoscopic control handle is visible. The background is a soft, blue and white gradient with a subtle rainbow light effect.





# BLI (Blue light imaging)



# BLI (Blue light imaging)



---

**FUJIFILM**  
Value from Innovation




# BLI (Blue light imaging)

---



# BLI + Zoom





# BLI + Zoom




# BLI + Zoom





# Classificazione di Parigi



# Classificazione di Kioto

## Subtypes of LST<sup>†</sup> lesions: Morphological classification of LST lesions and their correspondence in the Paris-Japanese classification

<u>Subtypes of LST</u>	<u>Classification of type 0</u>
<b>LST granular (LST-G)</b>	
Homogenous type	0-IIa
Nodular mixed type	0-IIa, 0-Is + IIa, 0-IIa + Is
<b>LST non-granular (LST-NG)</b>	
Flat elevated	0-IIa
Pseudo-depressed type	0-IIa + IIc, 0-IIc + IIa



**IIa**



**IIa + Is**

















**IIa**



**IIc + IIa**

<sup>†</sup> The term 'LST (laterally spreading tumor)' refers to the lateral growth of lesions at least 10 mm in diameter; this is in opposition to traditional polypoid (upward growth) or flat and depressed lesions (downward growth).




# Kudo classification

I		Round pit (normal pit)		Normal mucosa
II		Asteroid pit		Type II pit pattern is specific for hyperplasia. Also, superficial type serrated adenoma and SSA/P show this pit like pattern.
III <sub>s</sub>		Tubular or round pit that is smaller than the normal pit (type I)		Regular pattern → intramucosal lesion
III <sub>L</sub>		Tubular or round pit that is larger than the normal pit (type I)		
IV		Dendritic or gyrus-like pit		Irregular pattern → mucosal-submucosal deep invasion
V <sub>i</sub>		Irregular arrangement and sizes of III <sub>L</sub> , III <sub>s</sub> , IV type pit pattern		
V <sub>N</sub>		Loss or decrease of pits with an amorphous structure		Nonstructure pattern → Submucosal deep invasion



# NICE classification

## NBI International Colorectal Endoscopic (NICE) Classification\*









	Type 1	Type 2	Type 3
<b>Color</b>	Same or lighter than background	Browner relative to background (verify color arises from vessels)	Brown to dark brown relative to background; sometimes patchy whiter areas
<b>Vessels</b>	None, or isolated lacy vessels coursing across the lesion	Brown vessels surrounding white structures**	Has area(s) of disrupted or missing vessels
<b>Surface Pattern</b>	Dark or white spots of uniform size, or homogeneous absence of pattern	Oval, tubular or branched white structure surrounded by brown vessels**	Amorphous or absent surface pattern
<b>Most likely pathology</b>	<b>Hyperplastic</b>	<b>Adenoma***</b>	<b>Deep submucosal invasive cancer</b>
<b>Examples</b>			

\* Can be applied using colonoscopes with or without optical (zoom) magnification

\*\* These structures (regular or irregular) may represent the pits and the epithelium of the crypt opening.

\*\*\* Type 2 consists of Vienna classification types 3, 4 and superficial 5 (all adenomas with either low or high grade dysplasia, or with superficial submucosal carcinoma). The presence of high grade dysplasia or superficial submucosal carcinoma may be suggested by an irregular vessel or surface pattern, and is often associated with atypical morphology (e.g., depressed area).











# Classificazione di Sano

	I	II	IIIA	IIIB
Endoscopic Findings				
				
Histopathology	Meshed Capillary Vessels (-)  Normal Hyperplastic Polyp	* Meshed Capillary Vessels (+)  * Capillary Vessels Surround Mucosal Glands  Adenoma M*	Meshed Capillary Vessels Characterized by Branching, Curtailed Irregularity & Blind Endings  * Lack of Uniformity * High Density of Capillary Vessels  SM-Superficial**	* Nearly Avascular or Loose Microcapillary Vessels  SM-Deep***
	Treatment Strategy	No Treatment	Endoscopic Treatment (Polypectomy or EMR)	Surgical Treatment

\*Intramucosal Cancer \*\*SM Superficial Invasion (<1,000µm) \*\*\*SM Deep Invasion (≥1,000µm)



# Classificazione di Hiroshima

Type A			Microvessels are not observed or are extremely opaque	
Type B			Fine microvessels are observed around the surface pattern, and clear surface pattern can be observed via the nest of microvessels	
Type C	1			Microvessels comprise an irregular network, surface pattern observed via the microvessels are slightly non-distinct, and vessel diameter or distribution is homogeneous
	2			Microvessels comprise an irregular network, surface pattern observed via the microvessels are irregular, and vessel diameter or distribution is heterogeneous
	3			Surface pattern via the microvessels are invisible, irregular vessel diameter is thick, or the vessel distribution is heterogeneous, and avascular areas are observed

Color version available online

**Fig. 1.** NBI magnifying classification (Hiroshima classification).




pit pattern

non neoplastic pattern

neoplastic pattern

invasive cancer risk \*



• I

• II


• III L

• III S

• IV






• Vi

• Vn






vascular pattern




By Hiroyuki Kanao, 2009 (mod. Gizzi)



Stage 0	T <sub>is</sub>	No	M <sub>0</sub>
Stage I	T <sub>1</sub> ,	No	M <sub>0</sub>
Stage IIA	T <sub>3</sub>	No	M <sub>0</sub>
IIB	T <sub>4</sub>	No	M <sub>0</sub>
Stage IIIA	T <sub>1</sub> , T <sub>2</sub>	N <sub>1</sub>	M <sub>0</sub>
IIIB	T <sub>3</sub> , T <sub>4</sub>	N <sub>1</sub>	M <sub>0</sub>
IIIC	Any T	N <sub>2</sub>	M <sub>0</sub>
Stage IV	Any T	Any N	M <sub>1</sub>

# Narrow Band Imaging, Magnifying Chromoendoscopy, and Gross Morphological Features for the Optical Diagnosis of T1 Colorectal Cancer and Deep Submucosal Invasion: A Systematic Review and Meta-Analysis

Y. Backes, MD<sup>1</sup>, A. Moss, MBBS (Hons), MD<sup>2,3</sup>, J.B. Reitsma, MD, PhD<sup>4</sup>, P.D. Siersema, MD, PhD<sup>1,5</sup> and L.M.G. Moons, MD, PhD<sup>1</sup>



**Figure 2.** Receiver operating characteristic plot of the sensitivity and specificity of optical diagnosis of T1 CRC (a) and T1 CRC with deep submucosal invasion (b) of narrow band imaging (diamonds) and magnifying chromoendoscopy (circles) in the context of gross morphological features (squares). Scale of the size of points is based on the sample size of the studies. CRC, colorectal cancer.

## Study Highlights

### WHAT IS CURRENT KNOWLEDGE

- ✓ Accurate optical diagnosis of T1 colorectal cancer (CRC) and T1 CRC with deep submucosal invasion is important in guiding the decision to proceed with either piecemeal endoscopic resection, en-bloc endoscopic resection, or surgery.
- ✓ The systematic use of advanced imaging is not yet widely performed in daily clinical practice in Western countries.

### WHAT IS NEW HERE

- ✓ Advanced imaging techniques appear to result in a three-fold better recognition of T1 CRC and an almost twofold better recognition of deep invasion as compared with gross morphological features seen with conventional view.
- ✓ On the basis of current available literature, a preference for either microvessel or microsurface assessment with narrow band imaging or pit-pattern assessment with magnifying chromoendoscopy could not be observed.

# Obiettivo: discriminare

---

- Lesioni trascurabili
- Lesioni da rimuovere con l'endoscopia con tecniche standard
- Lesioni da rimuovere con tecniche di endoscopia avanzata
  - Lesioni chirurgiche




# Resezione endoscopica\*

---


- **Resezione radicale delle lesioni neoplastiche superficiali, cioè l'asportazione di lesioni confinate alla mucosa (m) o allo strato più superficiale della sottomucosa (sm), in assenza di invasione vascolare e/o linfatica.**
- **Resezione 'enbloc' (margini di resezione negativi o R0) in caso di sospetta invasione sottomucosa per permettere una corretta stadiazione e per stabilire il rischio di malattia residua (locale o metastatica)**
- **Tecniche endoscopiche sono: la Resezione Mucosa Endoscopica (EMR) e la Dissezione Endoscopica Sottomucosa (ESD)**

\* il mio paziente di ieri

# Resezione endoscopica




# EMR



- Cold snare polypectomy (ansa a freddo)
- Hot snare polypectomy or en bloc EMR
- Piecemeal EMR (in più frammenti)

# EMR



# Linee guida

---

Guideline

 Thieme

---

## **Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline**

---




---


Ferlitsch Monika et al. Colorectal polypectomy and... Endoscopy 2017; 49: 270–297




# EMR




# EMR



# EMR



# EMR



# EMR


---






# EMR

Sessile or Flat




# Polypectomia

---




# Polipectomia




# Polypectomia

---




# EMR







# EMR




# EMR




# EMR

---





# EMR





# EMR

---







# EMR



# EMR




# ESD





# ESD



# ESD





# ESD

## HybridKnife® per la resezione en-bloc

### I VANTAGGI

- ✔ Nessun cambio di strumento necessario, quindi riduzione dei tempi operatori
- ✔ Semplice ed immediata possibilità di regolazione della pressione del getto d'acqua
- ✔ Funzione di protezione meccanica e termica del cuscinetto d'acqua per tutta la durata della procedura
- ✔ Migliore visione del campo operatorio; il rischio di sanguinamento viene ridotto al minimo (compressione dei vasi sanguigni da parte del "cuscinetto d'acqua" creatosi)
- ✔ La pressione del getto d'acqua può essere dosata in modo variabile a seconda della lesione, dello strato del tessuto e dell'area di applicazione

erbe



# ESD

**FUJINON**  
FUJIFILM

**FlushKnife**  
*series*

Water Jet System — Maintaining the sharpness of the knife



# ESD

---


Single-Use Electrosurgical Knife

## DUALKNIFE J


New Jet Function to Help Shorten Procedure Times

**OLYMPUS**

Your Vision, Our Future



# ESD



# EFTR

## Endoscopic full-thickness resection in the colorectum with a novel over-the-scope device: first experience

### Authors

Arthur Schmidt<sup>1,\*</sup>, Peter Bauerfeind<sup>2,\*</sup>, Christoph Gubler<sup>2</sup>, Michael Damm<sup>1</sup>, Markus Bauder<sup>1</sup>, Karel Caca<sup>1</sup>

### Institutions

<sup>1</sup> Department of Gastroenterology and Oncology, Klinikum Ludwigsburg, Ludwigsburg, Germany


<sup>2</sup> Department of Gastroenterology and Hepatology, Zürich, Switzerland

Schmidt Arthur et al. New over-the-scope device for endoscopic full-thickness resection ... Endoscopy 2015; 47: 719–725


**Conclusions:** Full-thickness resection in the lower gastrointestinal tract with the novel FTRD was feasible and effective. Prospective studies are needed to further evaluate the device and technique.



# EFTR





# EFTR



# Risk for Incomplete Resection after Macroscopic Radical Endoscopic Resection of T1 Colorectal Cancer: A Multicenter Cohort Study

Y. Backes, MD<sup>1</sup>, W.H. de Vos tot Nederveen Cappel, MD, PhD<sup>2</sup>, J. van Bergeijk, MD, PhD<sup>3</sup>, F. ter Borg, MD, PhD<sup>4</sup>, M.P. Schwartz, MD, PhD<sup>5</sup>, B.W.M. Spanier, MD, PhD<sup>6</sup>, J.M.J. Geesing, MD<sup>7</sup>, K. Kessels, MD<sup>8</sup>, M. Kerkhof, MD, PhD<sup>9</sup>, J.N. Groen, MD<sup>10</sup>, F.H.J. Wolfhagen, MD, PhD<sup>11</sup>, T.C.J. Seerden, MD, PhD<sup>12</sup>, N. van Lelyveld, MD, PhD<sup>13</sup>, G.J.A. Offerhaus, MD, PhD<sup>14</sup>, P.D. Siersema, MD, PhD<sup>1,15</sup>, M.M. Lacle, MD, PhD<sup>14</sup> and L.M.G. Moons, MD, PhD<sup>1</sup> (on behalf of the Dutch T1 CRC Working Group)





\* Within the secondary surgery group, in 4 patients both residual luminal tumor and recurrent cancer during follow-up was observed

In the absence of histological high-risk factors, a 'wait-and-see' policy with limited follow-up is justified. Piecemeal resection and non-pedunculated morphology are independent risk factors for incomplete endoscopic resection of T1 CRC.

# Summary

---

- Le innovazioni tecnologiche in endoscopica consentono di operare una diagnostica accurata delle lesioni sospette T1
- La conseguente scelta appropriata della modalità di resezione endoscopica ha un ruolo fondamentale per il percorso successivo del paziente